Commission Implementing Regulation (EU) 2025/2154 of 17 October 2025 laying down good manufacturing practice for active substances used as starting materials in veterinary medicinal products in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council
Article 6Responsibilities of the quality unit
In force · version of Nov 16, 2025
1.The quality unit shall be responsible for both quality assurance and quality control.
2.The responsibilities of the quality unit shall include, among others, the following elements: (a) release or rejection of active substances and intermediates thereof; (b) establishment of a system to release or reject raw materials, intermediates, packaging and labelling materials; (c) review of production batch and laboratory control records for critical process parameters before release of the active substance; (d) approval of: (i) specifications and master production instructions; (ii) procedures impacting the quality of active substances or intermediates thereof; (iii) intermediate and active substance contract manufacturers; (iv) changes potentially impacting the quality of the active substance or intermediates thereof; (e) review and approval of all appropriate quality-related documents; (f) ensuring that: (i) critical deviations are investigated and resolved; (ii) self-inspections and/or internal audits are performed; (iii) quality-related complaints are investigated and resolved; (iv) effective systems are used for maintaining and calibrating critical equipment; (v) materials are appropriately tested and the results are reported; (vi) stability data to support retest of active substances or intermediates is available, where appropriate; (g) performance of product quality reviews referred to in Article 8.
3.The responsibilities of the quality unit shall be documented in writing and shall not be delegated.